(Q46585904)

English

Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

scientific article published in August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

psoriatic arthritis

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Désirée van der Heijde

2

object named as

Désirée van der Heijde

0 references

Dafna D. Gladman

6

object named as

Dafna D Gladman

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

Arthur Kavanaugh

1

object named as

Arthur Kavanaugh

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

author name string

Philip Mease

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Gerald G Krueger

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Juan Gómez-Reino

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Kim Papp

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Anna Baratelle

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Weichun Xu

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Surekha Mudivarthy

11

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Michael Mack

12

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Mahboob U Rahman

13

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Zhenhua Xu

14

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Julie Zrubek

15

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Anna Beutler

16

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

64

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

2504-2517

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

Psoriatic arthritis imaging: a review of scoring methods

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

Assessment of enthesitis in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

1 reference

https://api.crossref.org/works/10.1002%2FART.34436

21 January 2018

Identifiers

10.1002/ART.34436

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22378566

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46585904&oldid=2120590540"